76例先兆早产孕妇应用宫缩抑制剂治疗的疗效分析

目的分析及讨论催产素受体拮抗剂（依保）、β-肾上腺素受体激动剂（利托君）、硫酸镁三类宫缩抑制剂药物单用治疗先兆早产的临床效果。方法对14例使用依保、36例使用利托君和26例使用硫酸镁的先兆早产孕妇进行回顾性临床分析,对孕妇用药后的保胎效果、起效时间、不良反应及妊娠结局进行比较。结果依保组与利托君组的保胎成功率、起效时间、延长孕期时间之间无明显差异,但两组均显著高于硫酸镁组。不良反应以硫酸镁组的发生率最高,利托君组次之,依保组不良反应率最小。三组间新生儿状况改善及妊娠结局无明显差异。结论依保抑制宫缩作用强、显效快、成功率较高,安全有效,但费用较高。利托君作用与依保相当,且安全、低廉,可作为目前治疗先兆早产的首选药物。

Retrospective Clinical Study of Tocolytic Drugs used for the Prevention of Premature Labor

Objective To analyze and discuss the clinical effectiveness of prevention of premature labor using oxytodn antagonist （atosiba）, β-receptor agonist （ritodrine） and magnesium sulfate. Methods 76 cases of premature labor patients （14 were treated with atosiban, 36 with ritodrine and 26 cases with magnesium sulfate） were retrospectively analyzed for their effectiveness, complication and impact on pregnancy. Results Atosiban and ritodrine were more effective than magnesium sulfate in the prevention of premature labor. The rate of complication was in the order of magnesium sulfate group ritodrine group atosiban group. However, the outcome of pregnancy in these three groups was similar. Conclusion Although atosiban is expensive, it is relatively effectiveness and safe for the premature labor patients. The effectiveness of ritodrine is similar to atosiban and it can be used as first-line drug for the premature labor patients.